Overview

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Status:
Completed

Trial end date:
2021-03-05

Target enrollment:

Participant gender:

Summary

The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations.

Phase:

Phase 3

Details

Lead Sponsor:

Medivation, Inc.
Pfizer

Collaborator:

Medivation, Inc.

Treatments:

Poly(ADP-ribose) Polymerase Inhibitors
Talazoparib